Moderna: Vaccine Produced Strong Immune Results In Kids

Moderna's trial results indicate that smaller doses of their vaccine generate a strong immune response in children aged 6 to 11, with antibody response noted a month after the second dose. Although not yet peer-reviewed, Moderna plans to submit these findings to the FDA. Meanwhile, Pfizer is prepared to distribute its vaccine for children aged 5 to 11, pending FDA authorization. The FDA has indicated that the benefits of the vaccine outweigh the risks. According to the American Academy of Pediatrics, over 6 million children in the US have contracted COVID-19 since the pandemic began, out of 45 million total cases nationwide.

What did the FDA say about the benefits and risks of the vaccine?

How many kids in the US have tested positive for COVID since the pandemic began?